Subscriber access provided by LAURENTIAN UNIV
Article
Gastro-Resistant Insulin Receptor-Binding Peptide from Momordica charantia Improved the Glucose Tolerance in StreptozotocinInduced Diabetic Mice via Insulin Receptor Signaling Pathway Hsin-Yi Lo, Chia-Cheng Li, Feng-Yuan Chen, Jaw-Chyun Chen, Chien-Yun Hsiang, and Tin-Yun Ho J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.7b03583 • Publication Date (Web): 10 Oct 2017 Downloaded from http://pubs.acs.org on October 12, 2017
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 45
Journal of Agricultural and Food Chemistry
1
Gastro-Resistant Insulin Receptor-Binding Peptide from Momordica charantia Improved
2
the Glucose Tolerance in Streptozotocin-Induced Diabetic Mice via Insulin Receptor
3
Signaling Pathway
4
5
Hsin-Yi Lo,† Chia-Cheng Li,† Feng-Yuan Chen,† Jaw-Chyun Chen,‡ Chien-Yun Hsiang,§,*,
6
Tin-Yun Ho, ǁ,*
7
8
†
Graduate Institute of Chinese Medicine, China Medical University, Taichung, Taiwan
9
‡
Department of Medicinal Botany and Healthcare, Da-Yeh University, Changhua, Taiwan
10
§
Department of Microbiology, China Medical University, Taichung, Taiwan
11
ǁ
Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan
12
13
* Corresponding author. Tin-Yun Ho, Telephone: +886 4 22053366 x 3302. Fax: +886 4
14
22032295. E-mail address:
[email protected] 15
*Corresponding author. Chien-Yun Hsiang, Telephone: +886 4 22053366 x 2163. Fax: +886 4
16
22053764. E-mail address:
[email protected] 17
18
Short title: Gastro-resistant mcIRBP-9 improved glucose tolerance in diabetic mice
1
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
19
ABSTRACT
20
Momordica charantia is a commonly used food and has been used for the management
21
of diabetes. Our previous study has identified an insulin receptor (IR)-binding protein
22
(mcIRBP) from Momordica charantia. Here we identified the gastro-resistant
23
hypoglycemic bioactive peptides from protease-digested mcIRBP. By in vitro digestion
24
and IR kinase activity assay, we found that a 9-amino-acid-residue peptide, mcIRBP-9,
25
was a gastro-resistant peptide that enhanced IR kinase activities. mcIRBP-9 activated IR
26
signaling transduction pathway, resulting in the phosphorylation of IR, the translocation
27
of glucose transporter 4, and the uptake of glucose in cells. Intraperitoneal and oral
28
administration of mcIRBP-9 stimulated the glucose clearance by 30.91 ± 0.39% and
29
32.09 ± 0.38%, respectively, in streptozotocin-induced diabetic mice. Moreover, a pilot
30
study showed that daily ingestion of mcIRBP-9 for 30 days decreased the fasting blood
31
glucose levels and glycated hemoglobin (HbA1c) levels by 23.62 ± 6.14% and 24.06 ±
32
1.53%, respectively. In conclusion, mcIRBP-9 is a unique gastro-resistant bioactive
33
peptide generated after the digestion of mcIRBP. Furthermore, oral administration of
34
mcIRBP-9 improves both the glucose tolerance and the HbA1c levels in diabetic mice
35
via targeting IR signaling transduction pathway.
36
KEYWORDS: diabetes, gastro-resistant peptide, hypoglycemia, insulin receptor,
37
Momordica charantia 2
ACS Paragon Plus Environment
Page 2 of 45
Page 3 of 45
Journal of Agricultural and Food Chemistry
38
INTRODUCTION
39
Diabetes and its complications are severe global health problems.1 In 2015, there are
40
415 million people with diabetes worldwide and five million people die because of
41
diabetes. The estimated number of diabetic patients will increase by 55%, reaching
42
642 million patients by 2040. Furthermore, the global health cost due to diabetes is
43
USD 673 billion worldwide in 2015 and will reach to USD 802 billion by 2040.2
44
Diabetes is characterized by hyperglycemia, which is caused by defective insulin
45
secretion, resistance to insulin action, or a combination of both.1 Some foods have
46
showed functional activities on the regulation of blood glucose. For example,
47
jaboticaba (Myrciaria jaboticaba) is rich in polyphenols with anti-oxidative
48
activities.3 Intake of jaboticaba peels decreases glucose and insulin levels after the
49
second meal, suggesting that jaboticaba improves the insulin sensitivity in healthy
50
adults.4 Single oral administration of 1-deoxynojirimycin-enriched mulberry powder
51
significantly suppresses the elevation of postprandial blood glucose and the secretion
52
of insulin, suggesting that mulberry powder can be used as a dietary supplement for
53
the prevention of diabetes in healthy subjects.5 Furthermore, daily administration of
54
Ginkgo biloba L. leave dry extract improves the glycemic control in patients with type
55
2 diabetes.6 Three-month supplementation of ginger (Zingiber officinale) improves
56
glycemic indices in type 2 diabetic patients. Moreover, daily supplementation with 3
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
57
fermented red ginseng lowers postprandial glucose levels in subjects with impaired
58
fasting glucose or type 2 diabetes.7 In addition of food extracts, intake of soy proteins
59
significantly improves the glucose homeostasis in women with gestational diabetes.8
60
Conglutin gamma protein from Lupinus albus seeds has a relevant postprandial
61
hypoglycemic effect in humans, suggesting that it could potentially be used to manage
62
patients with impaired glucose metabolism.9 Additionally, oral administration of
63
insulin-like protein from Costus igneus significantly reduces the blood glucose levels
64
in streptozotocin (STZ)-induced diabetic Swiss mice via insulin signaling pathway.10
65
These studies therefore promise the beneficial effects of foods and food-derived
66
peptides on the regulation of blood glucose.
67
Bitter melon (Momordica charantia L.) is a commonly used vegetable and has
68
been widely used in traditional medicine for the treatment of diabetes in Asia. Daily
69
intake of bitter melon for four weeks shows hypoglycemic effects in patients with
70
type 2 diabetes.11 Bitter melon decreases fasting blood glucose levels and lowers 2-h
71
plasma glucose levels after oral glucose tolerance test in type 2 diabetic patients.
72
However, no patient experiences a symptomatic hypoglycemic event or has a
73
documented blood glucose level < 60 mg/dL, suggesting the beneficial effects and
74
safety of bitter melon consumption on glucose homeostasis.11 Supplementation of
75
bitter melon in the diet decreases the activities of maltase and lactase in the intestines 4
ACS Paragon Plus Environment
Page 4 of 45
Page 5 of 45
Journal of Agricultural and Food Chemistry
76
of type 1 diabetic rats, also suggesting the beneficial role of bitter melon on the
77
management of diabetes.12 In previous study, we have identified a hypoglycemic
78
polypeptide,
79
(mcIRBP).13,14 A 19-amino-acid-residue consensus peptide, mcIRBP-19, has been
80
further identified from mcIRBP.15 mcIRBP-19 is a putative IR-binding and blood
81
glucose-lowering bioactive peptide motif with a β-hairpin structure. Moreover,
82
mcIRBP-19 motif homologs are present in various plants belonging to different
83
taxonomic families. Because food proteins are usually cleaved into small peptides in
84
gastro-intestinal tracts, we characterized the gastro-resistant mcIRBP-derived peptides
85
and investigated the hypoglycemic effects of the identified peptide in STZ-induced
86
type 1 diabetic mice. IR kinase activity assay, glucose uptake activity assay, Western
87
blot, immunohistochemical staining (IHC), and immunofluorescence (IF) were
88
performed to elucidate the hypoglycemic mechanisms of peptides. Fasting blood
89
glucose and glucose tolerance test were measured to analyze the blood glucose
90
homeostasis and glucose clearance of peptides. Our findings showed that a
91
gastro-resistant 9-mer peptide, mcIRBP-9, was a bioactive peptide of Momordica
92
charantia that targeted IR and improved the glucose tolerance in type 1 diabetic mice.
Momordica
charantia
insulin
receptor
93
94 5
ACS Paragon Plus Environment
(IR)-binding
protein
Journal of Agricultural and Food Chemistry
95
MATERIALS AND METHODS
96
Chemicals. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO)
97
unless indicated. [γ-32P] ATP, [3H]-2-deoxy-D-glucose, and [125I]-insulin were
98
purchased from Perkin Elmer (Boston, MA). Rabbit polyclonal antibodies against IR,
99
phospho-phosphoinositide-dependent kinase 1 (PDK1), Akt, phospho-Akt (Thr308),
100
phospho-Akt (Ser473), and phospho-glycogen synthase kinase 3β (GSK-3β) was
101
purchased from Cell Signaling (Beverly, MA). Rabbit polyclonal antibody against
102
glucose transporter 4 (GLUT4) was purchased from Millipore (Temecula, CA).
103
Rabbit polyclonal antibody against phospho-IRβ (Tyr1162/Tyr1163) and mouse
104
monoclonal antibody against β-actin were purchased from Santa Cruz (Santa Cruz,
105
CA). Alexa Fluor 633-conjugated goat anti-rabbit IgG secondary antibody was
106
purchased from Invitrogen (Eugene, OR). Insulin (Actrapid®) was purchased from
107
Novo Nordisk (Kalundborg, Denmark).
108
109
Cell Lines. 3T3-L1 preadipocytes were purchased from Bioresource Collection
110
Research Center (Hsinchu, Taiwan). 3T3-L1 preadipocytes were maintained in
111
Dulbecco's modified Eagle medium (Life Technologies, Gaithersburg, MD)
112
supplemented with 10% calf serum (Life Technologies, Gaithersburg, MD). Cells
113
were incubated at 37°C in a humidified atmosphere containing 5% CO2. 6
ACS Paragon Plus Environment
Page 6 of 45
Page 7 of 45
Journal of Agricultural and Food Chemistry
114
115
In Vitro Digestion and Peptide Synthesis. All Peptides were synthesized by
116
PeptideSynTM technology (LifeTein, Somerset, NJ). Peptides with purities over 95%
117
were used in this study. mcIRBP-19 (RVRVWVTERGIVARPPTIG), a consensus
118
peptide motif of mcIRBP, is a putative IR-binding and blood glucose-lowering
119
peptide with a β-hairpin structure.15 mcIRBP-19 peptide was subjected to in vitro
120
digestion to identify the gastro-resistant peptide fragments in this study. In vitro
121
digestion was performed as described previously.15 Briefly, mcIRBP-19 was digested
122
by pepsin in a simulated gastric fluid (34.2 mM NaCl, 80 mM HCl, pH 3.0) at 37°C
123
for 30 min and then digested by pancreatin in a simulated intestinal fluid (100 mM
124
KH2PO4, 30 mM NaOH, pH 7.0) at 37°C for 60 min. The digestive peptide fragments
125
were identified by liquid chromatography-tandem mass spectrometry using an
126
Ultimate capillary LC system (LC Packings, Amsterdam, The Netherlands) coupled to
127
a QSTARXL quadrupole-time of flight mass spectrometer (Applied Biosystem/MDS
128
Sciex, Foster City, CA).
129
130
IR Kinase Activity Assay and Kinetic Analysis. IR kinase activity assay was
131
performed as described previously.15 Briefly, 0.5 µM or various amounts of peptides
132
were mixed with IR protein (Sigma-Aldrich, St. Louis, MO) and kinase buffer (25 7
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
133
mM HEPES, pH 7.6, 25 mM MgCl2, 100 µM ATP, 100 µM sodium orthovanadate,
134
2.5 mg/mL poly(Glu·Tyr), 25 µCi/mL [γ-32P]ATP). The resulting mixture was
135
incubated at 30°C for 10 min, spotted on chromatography papers, and then soaked in
136
10% trichloroacetic acid to precipitate poly(Glu·Tyr). The radioactivity incorporated
137
into the precipitated poly(Glu·Tyr) was measured by scintillation counter (Beckman
138
Coulter, Fullerton, CA). One unit (U) of kinase activity was determined as
139
transferring 1 pmol of phosphate from [γ-32P]ATP to poly(Glu·Tyr) per minute at
140
30°C. Vmax and KM values were calculated by fitting the data to the Michaelis-Menten
141
equation.
142
143
Glucose Uptake Assay. Glucose uptake assay was performed in fully
144
differentiated 3T3-L1 adipocytes, prepared as described previously.16 3T3-L1
145
adipocytes were cultured in 24-well plates. After a 4.5-h starvation, cells were
146
incubated in Krebs-Ringer bicarbonate buffer (118 mM NaCl, 4.7 mM KCl, 1.3 mM
147
CaCl2, 1.2 mM MgSO4, 1.2 mM Na2HPO4, 2% bovine serum albumin, 0.5 mM
148
glucose, 25 mM NaHCO3, pH 7.4), treated with various amounts of peptides for 30
149
min at 37°C, and treated with [3H]-2-deoxy-D-glucose (0.1 µCi/assay) for an
150
additional 10 min. Cells were then solubilized in 0.1% sodium dodecyl sulfate (SDS),
151
and the radioactivity incorporated into the cells was measured by scintillation counter 8
ACS Paragon Plus Environment
Page 8 of 45
Page 9 of 45
Journal of Agricultural and Food Chemistry
152
(Beckman Coulter, Fullerton, CA). Relative radioactivity was presented as the
153
comparison of radioactivity relative to solvent-treated cells. Effective concentration at
154
50% (EC50) was determined as the concentration of peptide required to increase
155
glucose uptake by 50% relative to solvent-treated cells.
156
157
IR-Binding Assay. IR-binding assay was performed as described previously with
158
slight modification.17 Briefly, fully differentiated 3T3-L1 adipocytes were incubated
159
with different amounts of mcIRBP-9 for 15 min at 25°C. [125I]-Insulin was added and
160
incubated for 90 min at 16°C. Cells were then scraped and centrifuged at 3,000 xg for
161
10 min. The supernatant containing unbound ligands was removed. The radioactivity
162
of cell pellet containing bound
163
counter (Beckman Coulter, Fullerton, CA).
125
I-labeled insulin was measured by scintillation
164
165
Western Blot Analysis. Fully differentiated 3T3-L1 adipocytes were treated with
166
0.5 µM insulin or various amounts of mcIRBP-9 at 37°C for 30 min. Cells were then
167
lyzed with RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.5% sodium
168
deoxycholate, 0.1% SDS, 150 mM sodium chloride, 2 mM EDTA, 50 mM sodium
169
fluoride) containing protease/phosphatase
170
Technology, Boston, MA). Protein samples (50 µg) were separated by 10%
inhibitor cocktail (Cell Signaling
9
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
171
SDS-polyacrylamide gel electrophoresis and transferred electrophoretically to
172
nitrocellulose membranes. Membranes were then probed with primary antibodies and
173
the bound antibody was detected with peroxidase-conjugated secondary antibodies
174
followed by chemiluminescence (Phototope®-HRP Western detection kit, New
175
England Biolabs, Ipswich, MA) and exposed by autoradiography. Bands on the X-ray
176
films were measured using Gel-Pro® Analyzer (Media Cybernetics, Silver Spring,
177
MD). Quantitative data were normalized by internal control (β-actin) and further
178
expressed as fold, which is presented as the comparison with the amount relative to
179
mock.
180
181
Animal Experiments. C57BL/6J mice (6-week old, male) were purchased from
182
National Laboratory Animal Center (Taipei, Taiwan). Mouse experiments were
183
conducted under ethics approval from China Medical University Animal Care and
184
Use Committee (Permit No. 104-75-N). Mice were maintained under a 12:12
185
light-dark cycle with free access to water and standard diet (#5001, LabDiet, St Louis,
186
MO) unless indicated.
187
To induce type 1 diabetes, C57BL/6J mice were intraperitoneally injected with 50
188
mg/kg STZ for five consecutive days. Two weeks later, fasting blood glucose levels
189
and fasting insulin levels were measured using glucometer (Draw-In, Scienco 10
ACS Paragon Plus Environment
Page 10 of 45
Page 11 of 45
Journal of Agricultural and Food Chemistry
190
Technology, Taipei, Taiwan) and insulin enzyme-linked immunosorbent assay kit
191
(Millipore, St. Charles, MO), respectively. The fasting insulin levels and the fasting
192
blood glucose levels of normal C57BL/6J mice were about 0.8 ng/ml and 75 mg/dL,
193
respectively. Mice were considered as type 1 diabetic if their fasting insulin and blood
194
glucose levels were about 0.4 ng/ml and ≥250 mg/dL, respectively.18 Intraperitoneal
195
glucose tolerance test (IPGTT) was performed as described previously.16 Briefly,
196
diabetic mice were fasted for 4 h and then given orally or intraperitoneally with
197
various amounts of mcIRBP-9 in phosphate-buffered saline (PBS) (137 mM NaCl,
198
1.4 mM KH2PO4, 4.3 mM Na2HPO4, 2.7 mM KCl, pH 7.2) 15 min before
199
intraperitoneal administration of 1 g/kg glucose solution. Blood glucose levels were
200
measured at indicated time after glucose challenge. Relative blood glucose area (%)
201
was presented as the comparison of the area under the curve (AUC) relative to mock.
202
Glycated hemoglobin (HbA1c) levels were measured by DCA Vantage Analyzer
203
(Siemens Healthcare, Erlangen, Germany). For long-term study, body weight and
204
food uptake were measured every five days. Fasting blood glucose levels were
205
measured every 14 days. HbA1c levels, IPGTT, and IHC were performed on the 30th
206
day.
207
11
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
208
Immunohistochemical staining and Immunofluorescence. Parafilm-embedded
209
muscle tissue sections were deparaffinized and rehydrated, followed by quenching
210
endogenous tissue peroxides. Sections were then incubated with anti-GLUT4
211
antibody (1:100 dilution) at 40C overnight. IHC was performed according to
212
manufacturer's instructions (Histostain-Plus, Invitrogen, Camarillo, CA). For IF,
213
slides were further hybridized with Alexa Fluor 633-conjugated goat anti-rabbit IgG
214
secondary antibody (1:500 dilution) for 60 min. Images were captured using an
215
inverted confocal microscope (Leica TCS SP2; Leica Microsystems, Wetzlar,
216
Germany), with an excitation wavelength of 632 nm. GLUT4-positive area was
217
measured using ImageJ (Media Cybernetics, Bethesda, MD). The expression of
218
GLUT4 was calculated as (area occupied with brown or red color/area of whole tissue)
219
× 100.
220
221
Statistical Analysis. Data were presented as mean ± standard error. Data were
222
analyzed by one-way ANOVA and post hoc Bonferroni test using SPSS Statistics
223
version 20 (IBM, Armonk, NY). A p-value < 0.05 was considered as statistically
224
significant.
225
226 12
ACS Paragon Plus Environment
Page 12 of 45
Page 13 of 45
Journal of Agricultural and Food Chemistry
227
RESULTS
228
Identification of Gastro-Resistant Peptides within mcIRBP-19. We have
229
previously identified a 19-mer peptide (mcIRBP-19) that exhibits hypoglycemic
230
effects via affecting IR signaling transduction pathway.15 In vitro digestion was
231
further performed to identify the gastro-resistant peptides within mcIRBP-19.
232
Digestion of mcIRBP-19 by pepsin and pancreatin released 178 fragments, which
233
included 31 kinds of peptides ranging from 5 to 13 amino acid residues in length
234
(Figure 1A). Among 178 fragments, mcIRBP-9 (IVARPPTIG) accounted for the
235
majority (20.78%) of fragments, followed by mcIRBP-6 (RPPTIG) (11.8%),
236
mcIRBP-10 (GIVARPPTIG) (8.99%), and mcIRBP-7 (ARPPTIG) (7.87%).
237
238
Effects of Gastro-Resistant Peptides on IR Kinase Activities and Glucose
239
Uptake Activities. To identify whether these gastro-resistant peptides exhibited
240
IR-binding abilities, we chemically synthesized the peptides and evaluated their
241
IR-binding abilities by IR kinase activity assay and glucose uptake assay. IR is a
242
transmembrane protein and intrinsic tyrosine kinase. Upon binding to insulin, IR
243
kinase phosphorylates the IR substrate and consequently stimulates the uptake of
244
glucose by adipocytes.19 As shown in Figure 1B, IR kinase activities were activated
245
by 0.5 µM peptides. Kinase activity of IR reached 62.34 ± 1.64 U/ml in the presence 13
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
246
of mcIRBP-9, followed by mcIRBP-10 (53.17 ± 0.85 U/ml) and mcIRBP-11 (51.77 ±
247
0.76 U/ml). By contrast, kinase activity of IR reached 21.71 ± 0.50 U/ml in the
248
presence of mcIRBP-6. Glucose uptake assay in 3T3-L1 adipocytes also showed that
249
mcIRBP-9 and mcIRBP-10 stimulated the uptake of glucose by 50% at 0.47 ± 0.05
250
µM and 8.42 ± 0.87 µM, respectively, while other peptides increased the glucose
251
uptake by 50% at more than 20 µM. These findings suggested that mcIRBP-9 was a
252
better gastro-resistant peptide that stimulated IR kinase activities and enhanced the
253
uptake of glucose in cells.
254
255
Effects of mcIRBP-9 on IR Signaling Transduction Pathways. To further
256
analyze the mcIRBP-9-IR interaction and the mcIRBP-9-induced IR signaling
257
transduction pathway, we performed IR-binding assay, glucose uptake assay, and
258
Western blot in the presence of mcIRBP-9. Fully differentiated 3T3-L1 adipocytes
259
were incubated with various amounts of mcIRBP-9 and a fixed amount of 125I-insulin
260
and IR. The radioactivity of cell pellets was increased as the amount of mcIRBP-9
261
was increased, suggesting that mcIRBP-9 enhanced the binding of insulin to IR
262
(Figure 2A). However, the addition of non-radiolabeled insulin decreased the
263
radioactivity, suggesting that non-radiolabeled insulin blocked and abolished
264
mcIRBP-9-dependent enhancement of insulin binding with specificity. These findings 14
ACS Paragon Plus Environment
Page 14 of 45
Page 15 of 45
Journal of Agricultural and Food Chemistry
265
also suggested that mcIRBP-9 interacted with the sites different from the
266
insulin-binding site on IR. Furthermore, fully differentiated 3T3-L1 adipocytes were
267
treated with various amounts of mcIRBP-9 and 3H-glucose. The radioactivity in cells
268
was gradually increased as the amount of mcIRBP-9 was increased, suggesting that
269
mcIRBP-9 stimulated the uptake of glucose in cells (Figure 2B). Moreover, the
270
stimulation displayed a dose-dependent manner.
271
We further evaluated the IR-binding kinetic parameters of mcIRBP-9 by IR kinase
272
activity assay. Upon binding to ligands, the kinase activity of IR was activated. The
273
velocity and the affinity of insulin and mcIRBP-9 were therefore calculated on the
274
basis of IR kinase activities. As shown in Figure 2C, the radioactivity was increased
275
as the amount of mcIRBP-9 or insulin was increased. The radioactivity reached a
276
plateau when the concentration of insulin and mcIRBP-9 was ≥ 500 nM and 1 µM,
277
respectively. The hyperbolic shape of the radioactivity/concentration curve was
278
further expressed by the Michaelis-Menten equation and applied to determine the Vmax
279
and KM values of insulin and mcIRBP-9. The KM and Vmax values of insulin on IR
280
were 0.053 ± 0.002 nM and 34.86 ± 0.79 U/ml/10 min, respectively, while KM and
281
Vmax values of mcIRBP-9 were 0.07 ± 0.02 nM and 20.86 ± 1.16 U/ml/10 min,
282
respectively.
15
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
283
Western blot was further performed to elucidate the IR signaling transduction
284
affected by mcIRBP-9. Binding of ligands to the extracellular region of IR induces a
285
conformational change of IR, resulting in the autophosphorylation of tyrosine residues
286
on IR. IR activation subsequently leads to the activation of PDK1 and the
287
phosphorylation of Akt. Activated Akt then results in the phosphorylation and
288
inactivation of GSK-3β, which promotes glucose storage as glycogen. It also leads to
289
the expression and translocation of GLUT4 to the plasma membrane, which promotes
290
the uptake of glucose.19 As shown in Figure 3, insulin induced the phosphorylations
291
of IR, PDK1, and Akt, resulting in the phosphorylation of GSK-3β and the expression
292
of GLUT4. mcIRBP-9 had no effects on the total amounts of IR and Akt. However,
293
mcIRBP-9 induced the phosphorylation of IR, which was consistent with the
294
aforementioned IR kinase activity data. In addition, mcIRBP-9, like insulin,
295
stimulated the phosphorylation of PDK1, Akt, and GSK-3β, and the expression of
296
GLUT4. Moreover, effects of mcIRBP-9 displayed a dose-dependent manner.
297
Therefore, these findings suggested that mcIRBP-9 interacted with IR, activated the
298
IR signaling transduction pathway, and induced the uptake of glucose in cells.
299
300
Effects of mcIRBP-9 on the Glucose Clearance in Type 1 Diabetic Mice. The
301
glucose clearance ability of mcIRBP-9 was evaluated by IPGTT. In comparison with 16
ACS Paragon Plus Environment
Page 16 of 45
Page 17 of 45
Journal of Agricultural and Food Chemistry
302
other mouse strains, C57BL/6J mice are sensitive to STZ stimulation. Moreover, male
303
mice tend to be more susceptible to STZ-induced diabetes.20 Therefore, male
304
C57BL/6J mice were chosen in this study for the establishment of type 1 diabetes.
305
Type 1 diabetic mice were intraperitoneally injected or orally given with various
306
dosages of mcIRBP-9. Blood glucose levels were determined after glucose challenge.
307
In this study, we identified that mcIRBP-9 was a gastro-resistant peptide targeting IR.
308
Therefore, commercial drugs that targeted IR were suitable as positive controls in
309
animal experiments. Insulin is the only medication that interacts with IR. Injectable
310
insulin was therefore used as a positive control to compare the hypoglycemic effects
311
of mcIRBP-9 given by intraperitoneal injection. As shown in Figure 4A, the amounts
312
of blood glucose reached maximum levels at 60 min after glucose challenge in all
313
groups, except insulin. In comparison with mock, all treatments, except 0.5 nmol/kg
314
and 1 nmol/kg mcIRBP-9, significantly decreased the blood glucose levels starting
315
from 30 min after glucose tolerance. Injection with insulin, as expected, significantly
316
improved the glucose tolerance in type 1 diabetic mice. Injectable insulin at 2.5
317
nmol/kg decreased the blood glucose area by 24.95 ± 0.46%, while injection of
318
mcIRBP-9 at 2.5 nmol/kg and 20 nmol/kg decreased the blood glucose area by 13.28
319
± 0.39% and 30.91 ± 0.39%, respectively. No oral insulin is available for the
320
comparison of oral mcIRBP-9. All treatments, except 0.1 µnol/kg mcIRBP-9, 17
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
321
significantly decreased the blood glucose levels during the experiment period (Figure
322
4B). Oral administration of mcIRBP-9 at 20 µmol/kg decreased the blood glucose
323
area by 32.09 ± 0.38%. In comparison with mock, both intraperitoneal and oral
324
administrations of mcIRBP-9 significantly stimulated the clearance of glucose in a
325
dose-dependent manner. However, intraperitoneal injection of mcIRBP-9 at 10
326
nmol/kg and 20 nmol/kg displayed similar hypoglycemic activities to insulin, with no
327
statistical differences. These findings suggested that mcIRBP-9 given by both
328
injection and oral exhibited hypoglycemic effects in type 1 diabetic mice. Moreover,
329
the glucose clearance ability of mcIRBP-9 was comparable to that of insulin.
330
331
Long-Term Effects of mcIRBP-9 on the Regulation of HbA1c and Blood
332
Glucose Levels in Type 1 Diabetic Mice. Single administration of mcIRBP-9
333
improved the glucose tolerance in type 1 diabetic mice. We wondered whether
334
long-term administration of mcIRBP-9 was capable of regulating the HbA1c levels. A
335
pilot study of long-term effects was therefore performed by oral administration of low
336
dose (0.1 µmol/kg) and high dose (1 µmol/kg) of mcIRBP-9 to type 1 diabetic mice
337
for 30 consecutive days. As shown in Figure 5A, the average body weight of mice
338
was 19.59 ± 2.11 g/mouse on Day 0 and 20.64 ± 3.29 g/mouse on Day 30. No
339
significant change on the body weight was observed during the treatment period. 18
ACS Paragon Plus Environment
Page 18 of 45
Page 19 of 45
Journal of Agricultural and Food Chemistry
340
Fasting blood glucose levels were increased as the time was increased in both mock
341
group and low-dose mcIRBP-9 group (Figure 5B). However, high dose of mcIRBP-9
342
maintained the fasting blood glucose levels at about 300 mg/dL during the experiment
343
period. IPGTT showed that, in comparison with mock, 1 µmol/kg mcIRBP-9
344
significantly decreased the blood glucose levels starting from 30 min after glucose
345
tolerance (Figure 5C). Oral administration of mcIRBP-9 at 1 µmol/kg significantly
346
decreased the blood glucose area by 23.62 ± 6.14%. The HbA1c level was 7.55 ±
347
0.33% in mock group (Figure 5D). However, mcIRBP-9 significantly decreased the
348
levels of HbA1c by 24.06 ± 1.53%. The HbA1c level dropped to 5.73 ± 0.12% after a
349
30-day administration of high dose of mcIRBP-9. The expression and translocation of
350
GLUT4, a marker of IR signaling pathway, in skeletal muscle tissues was analyzed by
351
IHC and IF. IHC analysis showed that the amount of GLUT4 was increased in mice
352
given with 1 µmol/kg mcIRBP-9 (Figure 5E, middle panel). The GLUT4-positive area
353
was 62.92 ± 3.52% in mcIRBP-9 group and 5.13 ± 1.27% in mock group. Moreover,
354
IF analysis showed that mcIRBP-9 significantly stimulated the translocation of
355
GLUT4 to the plasma membrane (11.65±2.84% vs. 3.03±1.31%) (Fgure 5E, right
356
panel). Therefore, our findings suggested that long-term administration of mcIRBP-9
357
improved both the glucose tolerance and the HbA1c levels in diabetic mice via
358
targeting IR signaling transduction pathway. 19
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
359
360
361
DISCUSSION
362
In this study, we identified that mcIRBP-9 was a likely gastro-resistant peptide from
363
bitter melon that activated IR signaling transduction pathway and improved the
364
glucose tolerance in type 1 diabetic mice. There are several medications currently
365
available for diabetes. For example, dipeptidyl peptidase 4 (DPP-4) inhibitors prevent
366
the rapid catabolism of endogenous glucagon-like peptide 1 (GLP-1). GLP-1 analogs
367
slow the absorption of intestinal carbohydrate. Insulin secretagogues and peroxisome
368
proliferator-activated receptor (PPAR) agonists enhance the secretion and sensitivity
369
of insulin.21 Some studies have shown that food-derived peptides and molecules can
370
act like these diabetic medications.22 For example, whey proteins reduce postprandial
371
glucose levels and stimulate insulin release in healthy subjects and in subjects with
372
type 2 diabetes by reducing DPP-4 activity in the proximal bowel.23 Short bioactive
373
peptide Ile-Pro-Ala, occurring in hydrolysates of β-lactoglobulin, has been identified
374
as a moderate DPP-4 inhibitor from whey proteins.24 Berries are a rich source of
375
bioactive phenolic compounds that are able to bind and inhibit DPP-4. Anthocyanins,
376
predominantly delphinidin-3-arabinoside, from fermented berry beverages have the
377
potential to modulate DPP-4 and its substrate GLP-1, and to increase insulin secretion 20
ACS Paragon Plus Environment
Page 20 of 45
Page 21 of 45
Journal of Agricultural and Food Chemistry
378
in pancreatic β-cells.25 Bioactive peptide Ile-Pro, derived from enzymatic proteolysis
379
of defatted rice bran has been identified as an effective DPP-4 inhibitor in vitro.26 Soy
380
peptide (IAVPTGVA) and lupin peptide (LTFPGSAED) have been identified as
381
DPP-4 inhibitors that interact with DPP-4 and inhibit DPP-4 activities.27 Casein
382
glycomacropeptide-derived peptide, IPPKKNQDKTE, increases the glucose uptake in
383
insulin-resistant HepG2 cells and increases the phosphorylation of Akt and GSK-3β,
384
suggesting that casein glycomacropeptide-derived peptide plays a potential role in the
385
prevention and treatment of hepatic insulin resistance and type 2 diabetes.28 Curcumin,
386
a yellow pigment isolated from the rhizomes of Curcuma longa L (turmeric),
387
significantly reduces the number of prediabetic individuals and appears to improve the
388
overall function of β-cells.29 In vitro and in vivo studies indicate that curcumin is a
389
GLP-1 secretagogue that increases the secretion of endogenous GLP-1.30 Furthermore,
390
metformin, the most popular anti-diabetic drug, is developed based on a biguanide
391
compound isolated from French lilac.31
392
Some natural molecules that exhibit insulin-like functions have also been identified
393
from foods or plants. Stevioside, a natural sweetener and diterpene glycoside
394
extracted from Stevia rebaudiana (Bertoni), has been used as an anti-hyperglycemic
395
agent for the treatment of diabetes for decades.32 Stevioside increases the levels of
396
GLUT4 protein and the uptake of glucose in both L6 myotubes and 3T3-L1 21
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
397
adipocytes.33 Modasima A, an anthraquinone from the roots of Morinda longissima Y.
398
Z. Ruan (Rubiaceae), improves glucose uptake via activation of AMP-activated
399
protein kinase.34 Additionally, roseoside, epigallocatechin gallate, glycyrrhetinic acid,
400
dehydrotrametenolic acid, strictinin, isostrictinin, pedunculagin, epicatechin, and
401
christinin-A from medicinal plants have shown significant insulin-like and
402
antidiabetic activities.35 Few insulin-like proteins or peptides have been identified
403
from foods or medicinal plants. Polypeptide-p or p-insulin is an 11-kDa protein
404
extracted from bitter melon. Polypeptide-p decreases blood glucose levels in gerbils,
405
langurs, and humans when injected subcutaneously.36 Insulin-like protein (ILP) is a
406
5.7-kDa protein extracted from leaves of Costus igneus.37 ILP significantly increases
407
the uptake of glucose, the levels of insulin receptor susbtrate-1, and the translocation
408
of GLUT4 in differentiated L6 myotubes.10 It also decreases the levels of blood
409
glucose when administered orally in type 1 diabetic mice.38 Although these studies
410
suggest that the insulin-like molecules or peptides are present in foods or plants, there
411
are no direct evidences indicating that these natural molecules or peptides interact
412
with IR and activate the autophosphorylation of IR. Moreover, oral stability of these
413
peptides remains to be evaluated. In this study, we identified a gastro-resistant
414
9-amin-acid-residue peptide mcIRBP-9 in bitter melon that targeted IR, activated IR
415
signaling transduction pathway, and stimulated the glucose uptake in cells. 22
ACS Paragon Plus Environment
Page 22 of 45
Page 23 of 45
Journal of Agricultural and Food Chemistry
416
Additionally, a 30-day oral administration of mcIRBP-9 stimulated the glucose
417
clearance and decreased the HbA1c levels in diabetic mice, suggesting the oral
418
benefits of mcIRBP-9 on the regulation of blood glucose. However, because of the
419
low number of mice in the long-term study, more researches are needed to verify our
420
data.
421
After ingestion, proteins are usually digested to amino acid residues or small
422
peptides by pepsin in the stomach and pancreatin in the small intestine. Our previous
423
study has identified that oral administration of a 68-mer mcIRBP and a 19-mer
424
mcIRBP-19 displayed hypoglycemic effects in mice. It was reasonable to expect that
425
these proteins and peptides would be cleaved by gastrointestinal enzymes after
426
ingestion. Therefore, we performed in vitro digestion using simulated gastric and
427
intestinal fluids in the presence of pepsin and pancreatin, and found that mcIRBP-9
428
was a minimal gastro-resistant bioactive peptide that exhibited hypoglycemic activity
429
in mice when given orally. It raised a question. How could mcIRBP-9 be absorbed by
430
gastrointestinal tract? Small intestine is responsible for the absorption of more than
431
90% of nutrients, such as carbohydrates, proteins, lipids, water, vitamins, and
432
minerals. Endocytosis, phagocytosis, transcytosis, direct penetration, and paracellular
433
transport are responsible for the transport of peptides in the intestinal epithelia.39
434
Small molecules with less than 100-200 daltons can be absorbed through paracellular 23
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
435
pathways.40 The molecular weight of mcIRBP-9 was approximately 975 daltons made
436
it difficult to be transported by paracellular pathways. Intestinal epithelium is made up
437
of phospholipid bilayer membrane and cholesterol. Upon oral administration, peptides
438
must traverse through this lipoidal membrane before entering into systemic circulation.
439
If peptide is lack of lipophilicity, no passive absorption can be taken place. The amino
440
acid sequence (IVARPPTIG) of mcIRBP-9 consisted of five kinds of hydrophobic
441
amino acid residues, including Ala, Ile, Val, Pro, and Gly. Moreover, the estimated
442
Grand Average of Hydropathy value of mcIRBP was 0.689 using ProtParam Program
443
in ExPASy Server, suggesting the lipophilicity of mcIRBP-9.41 Therefore, passive
444
absorption by intestinal epithelium might be a potent transport mechanism of
445
mcIRBP-9 in the small intestine. The detailed transport mechanism of mcIRBP-9
446
remained to be further elucidated.
447
The kinetic parameters, including Vmax and KM values, were calculated by IR
448
kinase activities. Vmax represents the maximum rate at the saturated concentration of
449
substrate, while the Michaelis constant KM is the substrate concentration at which the
450
reaction rate is half of Vmax. KM is an inverse measure of the affinity of substrate for
451
the enzyme, which means that a small KM value indicates a high affinity for the
452
enzyme.42 In previous study, we have reported that the KM values of mcIRBP and
453
mcIRBP-19 were 0.13 ± 0.02 nM and 0.11 ± 0.01 nM, respectively, and the Vmax 24
ACS Paragon Plus Environment
Page 24 of 45
Page 25 of 45
Journal of Agricultural and Food Chemistry
454
values were 18.32 ± 0.40 U/ml/10 min and 17.27 ± 0.26 U/ml/10 min, respectively.15
455
In comparison with mcIRBP and mcIRBP-19, the KM value (0.07 ± 0.02 nM) of
456
gastro-resistant mcIRBP-9 was decreased, suggesting that mcIRBP-9 exhibited a high
457
affinity to IR. In addition, mcIRBP-9 displayed similar kinetic parameters with
458
insulin.
459
Some hypoglycemic peptides isolated from foods or plants stimulate the uptake of
460
glucose in vitro or in vivo without the evidences of IR interaction. Here we found that
461
mcIRBP-9 was a unique gastro-resistant 9-mer bioactive peptide of Momordica
462
charantia that targeted IR. Oral administration of mcIRBP-9 stimulated the clearance
463
of blood glucose in type 1 diabetic mice. A pilot study showed that daily ingestion of
464
mcIRBP-9 for 30 days improved the glucose tolerance and decreased the HbA1c
465
levels via IR signaling pathway. In conclusion, our findings might explain the potent
466
blood glucose-modulating effect of Momordica charantia after ingestion. Moreover,
467
mcIRBP-9 might be able to contribute to the anti-diabetic action of bitter melon.
468
469
470
FUNDING SOURCES
471
This work was supported by grants from Ministry of Science and Technology
472
(MOST104-2320-B-039-018-MY3 and MOST105-2320-B-039-017-MY3), China 25
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Page 26 of 45
473
Medical University (CMU104-H-01 and CMU104-H-02), and CMU under the Aim
474
for Top University Plan of the Ministry of Education, Taiwan.
475
476
477
NOTES
478
The authors declare no competing financial interest. Patents for mcIRBP-9 have been
479
approved by U.S. (US 8,697,649 B2 and US 9,029,326 B2), Europe (EP 2664622 B1),
480
Japan (JP 5676538 and JP 5947872), Taiwan (I588153), and China Patent Offices (ZL
481
201210164364.4).
482
483
484
ABBREVIATIONS USED
485
AUC, area under the curve; DPP-4, dipeptidyl peptidase 4; EC50, effective
486
concentration at 50%; GLP-1, glucagon-like peptide 1; GLUT4, glucose transporter 4;
487
GSK-3β, glycogen synthase kinase 3β; HbA1c, glycated hemoglobin; IF,
488
immunofluorescence; ILP, insulin-like protein; IPGTT, intraperitoneal glucose
489
tolerance test; IR, insulin receptor; mcIRBP, Momordica charantia insulin receptor
490
(IR)-binding
protein;
PBS,
phosphate-buffered
26
ACS Paragon Plus Environment
saline;
PDK1,
Page 27 of 45
Journal of Agricultural and Food Chemistry
491
phosphoinositide-dependent kinase 1; PPAR, peroxisome proliferator-activated
492
receptors; SDS, sodium dodecyl sulfate; STZ, streptozotocin; U, unit
27
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
493
494
495
496
497
Page 28 of 45
REFERENCES (1) American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2017, 40, S11-S24. (2)
International
Diabetes
Federation.
IDF
diabetes
atlas.
(7th
ed.).
http://www.diabetesatlas.org (2017.4.28)
498
(3) Leite, A. V.; Malta, L. G.; Riccio, M. F.; Eberlin, M. N.; Pastore, G. M.;
499
Maróstica Júnior, M. R. Antioxidant potential of rat plasma by administration of
500
freeze-dried jaboticaba peel (Myrciaria jaboticaba Vell Berg). J. Agric. Food Chem.
501
2011, 59, 2277-2283.
502
(4) Plaza, M.; Batista, Â. G.; Cazarin, C. B.; Sandahl, M.; Turner, C.; Östman, E.;
503
Maróstica Júnior, M. R. Characterization of antioxidant polyphenols from Myrciaria
504
jaboticaba peel and their effects on glucose metabolism and antioxidant status: A
505
pilot clinical study. Food Chem. 2016, 211, 185-197.
506
(5) Kimura, T.; Nakagawa, K.; Kubota, H.; Kojima, Y.; Goto, Y.; Yamagishi, K.;
507
Oita, S.; Oikawa, S.; Miyazawa, T. Food-grade mulberry powder enriched with
508
1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans.
509
J. Agric. Food Chem. 2007, 55, 5869-5874.
510
(6) Lasaite, L.; Spadiene, A.; Savickiene, N.; Skesters, A.; Silova, A. The effect of
511
Ginkgo biloba and Camellia sinensis extracts on psychological state and glycemic 28
ACS Paragon Plus Environment
Page 29 of 45
Journal of Agricultural and Food Chemistry
512
control in patients with type 2 diabetes mellitus. Nat. Prod. Commun. 2014, 9,
513
1345-1350.
514
(7) Shidfar, F.; Rajab, A.; Rahideh, T.; Khandouzi, N.; Hosseini, S.; Shidfar, S.
515
The effect of ginger (Zingiber officinale) on glycemic markers in patients with type 2
516
diabetes. J. Complement. Integr. Med. 2015, 12, 165-170.
517
(8) Jamilian, M.; Asemi, Z. The effect of soy intake on metabolic profiles of
518
women with gestational diabetes mellitus. J. Clin.Endocrinol. Metab. 2015, 100,
519
4654-4661.
520
(9) González-Santiago, A. E.; Vargas-Guerrero, B.; García-López, P. M.;
521
Martínez-Ayala, A. L.; Domínguez-Rosales, J. A.; Gurrola-Díaz, C. M. Lupinus albus
522
conglutin gamma modifies the gene expressions of enzymes involved in glucose
523
hepatic
524
10.1007/s11130-016-0597-7.
production
in
vivo.
Plant
Foods
Hum.
Nutr.
2017,
DOI
525
(10) Hardikar, M. R.; Varma, M. E.; Kulkarni, A. A.; Kulkarni, P. P.; Joshi, B. N.
526
Elucidation of hypoglycemic action and toxicity studies of insulin-like protein from
527
Costus igneus. Phytochemistry 2016, 124, 99-107.
528
(11) Fuangchan, A.; Sonthisombat, P.; Seubnukarn, T.; Chanouan, R.;
529
Chotchaisuwat, P.; Sirigulsatien, V.; Ingkaninan, K.; Plianbangchang, P.; Haines, S. T.
29
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
530
Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed
531
type 2 diabetes patients. J. Ethnopharmacol. 2011, 134, 422-428.
532
533
(12) Perla, V.; Jayanty, S. S. Biguanide related compounds in traditional antidiabetic functional foods. Food Chem. 2013, 138, 1574-1580.
534
(13) Lo, H. Y.; Ho, T. Y.; Lin, C.; Li, C. C.; Hsiang, C. Y. Momordica charantia
535
and its novel polypeptide regulate glucose homeostasis in mice via binding to insulin
536
receptor. J. Agric. Food Chem. 2013, 61, 2461-2468.
537
(14) Lo, H. Y.; Ho, T. Y.; Li, C. C.; Chen, J. C.; Liu, J. J.; Hsiang, C. Y. A novel
538
insulin receptor-binding protein from Momordica charantia enhances glucose uptake
539
and glucose clearance in vitro and in vivo through triggering insulin receptor signaling
540
pathway. J. Agric. Food Chem. 2014, 62, 8952-8961.
541
(15) Lo, H. Y.; Li, C. C.; Ho, T. Y.; Hsiang, C. Y. Identification of the bioactive
542
and consensus peptide motif from Momordica charantia insulin receptor-binding
543
protein. Food Chem. 2016, 204, 298-305.
544
(16) Lo, H. Y.; Hsiang, C. Y.; Li, T. C.; Li, C. C.; Huang, H. C.; Chen, J. C.; Ho, T.
545
Y. A novel glycated hemoglobin A1c-lowering traditional Chinese medicinal formula,
546
identified by translational medicine study. PLoS One 2014, 9, e104650.
30
ACS Paragon Plus Environment
Page 30 of 45
Page 31 of 45
Journal of Agricultural and Food Chemistry
547
(17) Gauguin, L.; Delaine, C.; Alvino, C. L.; McNeil, K. A.; Wallace, J. C.; Forbes,
548
B. E.; De Meyts, P. Alanine scanning of a putative receptor binding surface of
549
insulin-like growth factor-I. J Biol Chem. 2008, 283, 20821-20829.
550
(18) Chaudhry, Z. Z.; Morris, D. L.; Moss, D. R.; Sims, E. K.; Chiong, Y.; Kono,
551
T.; Evans-Molina, C. Streptozotocin is equally diabetogenic whether administered to
552
fed or fasted mice. Lab Anim. 2013, 47, 257-265.
553
554
(19) Chang, L.; Chiang, S. H.; Saltiel, A. R. Insulin signaling and the regulation of glucose transport. Mol. Med. 2004, 10, 65-71.
555
(20) Deeds, M. C.; Anderson, J. M.; Armstrong, A. S.; Gastineau, D. A.; Hiddinga,
556
H. J.; Jahangir, A.; Eberhardt, N. L.; Kudva, Y. C. Single dose streptozotocin-induced
557
diabetes: considerations for study design in islet transplantation models. Lab Anim.
558
2011, 45, 131-140.
559
560
(21) American Diabetes Association. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017, 40, S64-S74
561
(22) Grassi, D.; Desideri, G.; Mai, F.; Martella, L.; De Feo, M.; Soddu, D.; Fellini,
562
E.; Veneri, M.; Stamerra, C. A.; Ferri, C. Cocoa, glucose tolerance, and insulin
563
signaling: cardiometabolic protection. J. Agric. Food Chem. 2015, 63, 9919-9926.
31
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Page 32 of 45
564
(23) Geraedts, M. C.; Troost, F. J.; Fischer, M. A.; Edens, L.; Saris, W. H. Direct
565
induction of CCK and GLP-1 release from murine endocrine cells by intact dietary
566
proteins. Mol. Nutr. Food Res. 2011, 55, 476-484.
567
(24) Tulipano, G.; Sibilia, V.; Caroli, A. M.; Cocchi, D. Whey proteins as source
568
of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides 2011, 32,
569
835-838.
570
(25) Johnson, M. H.; de Mejia, E. G. Phenolic compounds from fermented berry
571
beverages modulated gene and protein expression to increase insulin secretion from
572
pancreatic β-cells in vitro. J. Agric.Food Chem. 2016, 64, 2569-2581.
573
(26) Hatanaka, T.; Inoue, Y.; Arima, J.; Kumagai, Y.; Usuki, H.; Kawakami, K.;
574
Kimura, M.; Mukaihara, T. Production of dipeptidyl peptidase IV inhibitory peptides
575
from defatted rice bran. Food Chem. 2012, 134, 797-802.
576
(27) Lammi, C.; Zanoni, C.; Arnoldi, A.; Vistoli, G. Peptides derived from soy and
577
lupin protein as dipeptidyl-peptidase IV inhibitors: in vitro biochemical screening and
578
in silico molecular modeling study. J. Agric. Food Chem. 2012, 64, 9601-9606.
579
(28) Song, J. J.; Wang, Q.; Du, M.; Li, T. G.; Chen, B.; Mao, X. Y. Casein
580
glycomacropeptide-derived
peptide
IPPKKNQDKTE
581
glucose-induced insulin resistance in HepG2 cells via activation of AMPK signaling.
582
Mol. Nutri. Food Res. 2017, 61, 1600301. 32
ACS Paragon Plus Environment
ameliorates
high
Page 33 of 45
Journal of Agricultural and Food Chemistry
583
(29) Chuengsamarn, S.; Rattanamongkolgul, S.; Luechapudiporn, R.; Phisalaphong,
584
C.; Jirawatnotai, S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care
585
2012, 35, 2121-2127.
586
(30) Kato, M.; Nishikawa, S.; Ikehata, A.; Dochi, K.; Tani, T.; Takahashi, T.;
587
Imaizumi, A.; Tsuda, T. Curcumin improves glucose tolerance via stimulation of
588
glucagon-like peptide-1 secretion. Mol. Nutri. Food Res. 2017, 61, 61, 1600471.
589
(31) Oubré, A. Y.; Carlson, T. J.; King, S. R.; Reaven, G. M. From plant to patient:
590
an ethnomedical approach to the identification of new drugs for the treatment of
591
NIDDM. Diabetologia 1997, 40, 614-617.
592
(32) Yadav, S. K.; Guleria, P. Steviol glycosides from Stevia: biosynthesis
593
pathway review and their application in foods and medicine. Crit. Rev. Food Sci. Nutr.
594
2012, 52, 988-998.
595
(33) Bhasker, S.; Madhav, H.; Chinnamma, M. Molecular evidence of
596
insulinomimetic property exhibited by steviol and stevioside in diabetes induced L6
597
and 3T3L1 cells. Phytomedicine 2015, 22, 1037-1044.
598
(34) Nguyen, P. H.; Choi, H. S.; Ha, T. K.; Seo, J. Y.; Yang, J. L.; Jung, D. W.;
599
Williams, D. R.; Oh, W. K. Anthraquinones from Morinda longissima and their
600
insulin mimetic activities via AMP-activated protein kinase (AMPK) activation.
601
Bioorg. Med. Chem. Lett. 2017, 27, 40-44. 33
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
602
(35) Patel, D. K.; Prasad, S. K.; Kumar, R.; Hemalatha, S. An overview on
603
antidiabetic medicinal plants having insulin mimetic property. Asian Pac. J. Trop.
604
Biomed. 2012, 2, 320-330.
605
606
(36) Krawinkel, M. B.; Keding, G. B. Bitter gourd (Momordica charantia): A dietary approach to hyperglycemia. Nutr. Rev. 2006, 64, 331-337.
607
(37) Joshi, B. N.; Munot, H.; Hardikar, M.; Kulkarni, A. A. Orally active
608
hypoglycemic protein from Costus igneus N. E. Br.: an in vitro and in vivo study.
609
Biochem. Biophy. Res. Commun. 2013, 436, 278-282.
610
611
612
613
(38) Hegde, P. K.; Rao, H. A.; Rao, P. N. A review on Insulin plant (Costus igneus Nak). Pharmacogn. Rev. 2014, 8, 67-72. (39) Fosgerau, K.; Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov. Today 2015, 20, 122-128.
614
(40) Camenisch, G.; Alsenz, J.; van de Waterbeemd, H.; Folkers, G. Estimation of
615
permeability by passive diffusion through Caco-2 cell monolayers using the drugs'
616
lipophilicity and molecular weight. Eur. J. Pharm. Sci. 1998, 6, 317-324.
617
(41) Gasteiger, E.; Hoogland, C.; Gattiker, A.; Duvaud, S.; Wilkins, M. R.; Appel,
618
R. D.; Bairoch, A. Protein identification and analysis tools on the ExPASy server. In
619
The proteomics protocols handbook; Walker J. M., Ed.; Humana Press: New York,
620
NY, 2005, pp. 571-607. 34
ACS Paragon Plus Environment
Page 34 of 45
Page 35 of 45
Journal of Agricultural and Food Chemistry
621
622
(42) Grima, R.; Walter, N. G.; Schnell, S. Single-molecule enzymology à la Michaelis-Menten. The FEBS J. 2014, 281, 518-530.
35
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Page 36 of 45
623
FIGURE CAPTIONS
624
Figure 1. Identification of gastro-resistant IR-binding peptides within mcIRBP-19. (A)
625
Location and distribution of gastro-resistant peptides. The amino acid sequences of
626
mcIRBP-19 are shown at the top. The relative positions of gastro-resistant peptide
627
fragments are shown by solid lines. The thickness and color of line represent the
628
content (%) of peptide in the mcIRBP-19-digested fragments. Lines in red, blue, green,
629
and purple represent >20%, 6-20%, 3-5%, and 20
mcIRBP-11
ERGIVARPPTIG
>20
mcIRBP-10
ERGIVARPPTIG
8.42 ± 0.87
mcIRBP-9
ERGIVARPPTIG
0.47 ± 0.05
mcIRBP-8
ERGIVARPPTIG
>20
mcIRBP-7
ERGIVARPPTIG
>20
mcIRBP-6
ERGIVARPPTIG
>20
mcIRBP-9-1
ERGIVARPPTIG
>20
mcIRBP-9-2
ERGIVARPPTIG
>20
mcIRBP-9-3
ERGIVARPPTIG
>20
Peptide
40
ACS Paragon Plus Environment
IR kinase activity (U/ml)
Page 40 of 45
Page 41 of 45
Journal of Agricultural and Food Chemistry
Figure 2 (A)
(B) 2.5
3
2
Relative radioactivity
Relative radioactivity
***
3.5
***
** 1.5
1
0.5
2.5 2 1.5 1 0.5 0
0
0
mcIRBP-9 (µM) Cold insulin
0 ―
1 ―
2.5 ―
5 ―
10 ―
0.5
1
2.5
5
10
20
10 mcIRBP-9 concentration (µM)
+
8000
8000
7000
7000 Radioactivity (dpm)
Radioactivity (dpm)
(C)
6000 5000 4000 3000 2000 1000
6000 5000 4000 3000 2000 1000
0
0 0
500
1000
1500
2000
2500
0
Insulin concentration (nM)
2000
4000
6000
8000
mcIRBP-9 concentration (nM) 41
ACS Paragon Plus Environment
10000
Journal of Agricultural and Food Chemistry
Page 42 of 45
Figure 3
mcIRBP-9 (µM) Mock
Insulin
1
2.5
5
IR p-IR p-PDK1 Akt p-Akt (Thr308) p-Akt (Ser473) p-GSK-3β GLUT4 β-Actin
12
Fold relative to mock
10
Insulin
*
mcIRBP-9 1µM mcIRBP-9 2.5µM
8
*
**
*
mcIRBP-9 5µM
** *
6 *
** *
*
4
*
*
2 0 IR
p-IR
p-PDK-1
Akt
p-Akt p-Akt GSK-3β GLUT-4 (Thr308) (Ser473)
42
ACS Paragon Plus Environment
Page 43 of 45
Journal of Agricultural and Food Chemistry
Figure 4 (A) 110 Relative blood glucose area (%)
1000
Blood glucose (mg/dL)
900 800 700 600 500
Mock Insulin 2.5 nmol/kg mcIRBP-9 0.5 nmol/kg mcIRBP-9 1 nmol/kg mcIRBP-9 2.5 nmol/kg mcIRBP-9 5 nmol/kg mcIRBP-9 10 nmol/kg mcIRBP-9 20 nmol/kg
400 300 200 100
***
**
100 90 80
***
70 60 50
0 0
30
60
90
120
180
Mock Insulin
240
0.5
1
2.5
5
10
20
mcIRBP-9 dosage (nmol/kg)
Time (min)
(B) 110 Relative blood glucose area (%)
1000 900 Blood glucose (mg/dL)
800 700 600 500
Mock mcIRBP-9 0.1 µmol/kg mcIRBP-9 0.5 µmol/kg mcIRBP-9 1 µmol/kg mcIRBP-9 2.5 µmol/kg mcIRBP-9 5 µmol/kg mcIRBP-9 10 µmol/kg mcIRBP-9 20 µmol/kg
400 300 200 100 0 0
30
60
90
100
***
** 90 80 70 60 50
120
180
Mock
240
Time (min)
0.1
0.5
1
2.5
5
mcIRBP dosage (µmol/kg) 43
ACS Paragon Plus Environment
10
20
Journal of Agricultural and Food Chemistry
Page 44 of 45
Figure 5 (A)
(C)
(D)
(B)
(E)
Mock
5.13±1.27%
3.03±1.31%
mcIRBP-9
62.92±3.52% **
44
ACS Paragon Plus Environment
11.65±2.84%**
Page 45 of 45
Journal of Agricultural and Food Chemistry
Table of Contents Graphics
mcIRBP
mcIRBP-9 in vitro digestion
45
ACS Paragon Plus Environment